发布求助
文献互助 智能选刊 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

筛选
英文 中文
Carbetapentane citrate. 柠檬酸卡贝塔戊烷。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-05 DOI: 10.1016/bs.podrm.2019.10.002
Ahmed S Abo Dena, Alaa M Ali, Ibrahim M El-Sherbiny
{"title":"Carbetapentane citrate.","authors":"Ahmed S Abo Dena,&nbsp;Alaa M Ali,&nbsp;Ibrahim M El-Sherbiny","doi":"10.1016/bs.podrm.2019.10.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.002","url":null,"abstract":"<p><p>Carbetapentane citrate, a non-opioid centrally-acting antitussive drug, is a common treatment for cough associated with other diseases such as common cold and respiratory tract infections. Its mode of action is very close to that of atropine; since it acts at the level of the peripheral parasympathetic nerve endings. The drug reaches its maximum plasma concentration (C<sub>max</sub>) 2h after administration, and it has a plasma half-life of 2.3h in case of oral administration. Due to its clinical importance, there are many analytical methods in the literature for carbetapentane determination. In addition, it is crucial to collect its analytical results in a single chapter so as to allow researchers to easily interpret their experimental data. Here, we provide the analytical profile of carbetapentane citrate with a brief description/interpretation of each analysis.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37731930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Azilsartan medoxomil. 阿齐沙坦酯钾。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.001
Abdulrahman A Al-Majed, Ahmed H H Bakheit, Ali Al-Muhsin, Hamad M Al-Kahtani, Ali S Abdelhameed
{"title":"Azilsartan medoxomil.","authors":"Abdulrahman A Al-Majed,&nbsp;Ahmed H H Bakheit,&nbsp;Ali Al-Muhsin,&nbsp;Hamad M Al-Kahtani,&nbsp;Ali S Abdelhameed","doi":"10.1016/bs.podrm.2019.10.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.001","url":null,"abstract":"<p><p>Azilsartan is used for treatment of the high blood pressure (hypertension). Reducing high blood pressure enables avoid strokes, heart attacks and problems of kidneys. Azilsartan comes under the name angiotensin receptor blocker (ARBs) as a class of drugs. It acts by relaxing blood vessels to make it easier for blood to flow. Azilsartan Medoxomil's a comprehensive profile containing the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods. Other studies on this drug substance include drug stability, Pharmaceutical Applications, Mechanism of Action, Pharmacodynamics, and a Dosing Information are reviewed. At the end of this profile, there are more than sixty references were listed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isotretinoin. 异维甲酸。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.005
Nasr Y Khalil, Ibrahim A Darwish, Abdulmohsen A Al-Qahtani
{"title":"Isotretinoin.","authors":"Nasr Y Khalil,&nbsp;Ibrahim A Darwish,&nbsp;Abdulmohsen A Al-Qahtani","doi":"10.1016/bs.podrm.2019.10.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.005","url":null,"abstract":"<p><p>Isotretinoin is chemically named as: (2Z, 4E, 6E, 8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid. It is an orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. It acts primarily by reducing sebaceous gland size and sebum production, and as a result alters skin surface lipid composition. Using isotretinoin for 1-2mg/kg/day for 3-4 months produces 60%-95% clearance of inflammatory lesions in patients with acne. Doses as low as 0.1mg/kg/day have also proven successful in the clearance of lesions. Encouraging results have also been seen in small numbers of patients with rosacea, Side effects affecting the mucocutaneous system and raised serum triglyceride levels occur in most patients receiving isotretinoin. Isotretinoin is strictly contraindicated in women of childbearing potential. This profile discusses and explains names of isotretinoin, its physical and chemical characteristics. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, and pharmacology.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piroxicam. 吡罗昔康。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-18 DOI: 10.1016/bs.podrm.2019.10.007
Gamal A E Mostafa, Abdullah S Al-Dosseri, Abdullah A Al-Badr
{"title":"Piroxicam.","authors":"Gamal A E Mostafa,&nbsp;Abdullah S Al-Dosseri,&nbsp;Abdullah A Al-Badr","doi":"10.1016/bs.podrm.2019.10.007","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.007","url":null,"abstract":"<p><p>A comprehensive profile of piroxicam including the nomenclatures, formulae, elemental composition, appearance, uses and applications. The methods which were utilized for the preparation of the drug substance and their respective schemes are outlined. The physical characteristics of the drug including the ionization constant, solubility, x-ray powder diffraction pattern, differential scanning calorimetry, thermal behavior and spectroscopic studies are described. The methods which were used for the analysis of the drug substance in bulk drug and/or in pharmaceutical formulations including the compendial, spectrophotometric, electrochemical and the chromatographic methods are reported. The stability, toxicity, pharmacokinetics, bioavailability, drug evaluation, comparison, in addition to compiled reviews on the drug substance are involved. Finally, more than four hundred and fifty references are listed at the end of this profile.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emtricitabine. Emtricitabine。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.003
Abdulrahman A Al-Majed, Ahmed H H Bakheit, Bakr Mohammed Al-Qahtani, Hamad M Al-Kahtani, Ali S Abdelhameed
{"title":"Emtricitabine.","authors":"Abdulrahman A Al-Majed,&nbsp;Ahmed H H Bakheit,&nbsp;Bakr Mohammed Al-Qahtani,&nbsp;Hamad M Al-Kahtani,&nbsp;Ali S Abdelhameed","doi":"10.1016/bs.podrm.2019.10.003","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.003","url":null,"abstract":"<p><p>Emtricitabine (Emtriva, FTC) is an antiviral medicine which decreases the body's amount of HIV. Emtricitabine on of Anti-HIV drugs slow down or protect the immune system against damage and reduce the risk of diseases related to developing of AIDS. Emtricitabine use also for treatment of hepatitis B virus. Emtricitabine is a drug class known as nucleoside reversing transcriptase inhibitors (NRTIs). In view of Emtricitabine's clinical significance, a thorough review of the physical and pharmaceutical characteristics and details of the multiple analytical techniques used to test the drug in pharmaceutical and biological systems was conducted. The methods investigated include identification test, Spectroscopy, chromatography, electrochemicals, and Thermal. Beside the analytical profile, the degradation and stability of Emtricitabine, its pharmacology and pharmacokinetics, Pharmaceutical Applications, Mechanism of Action, dosage forms and dose, ADME profile, and interactions have been debated.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37731931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Erlotinib. 埃洛替尼。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.004
Ahmed A Abdelgalil, Hamad M Al-Kahtani, Fahad I Al-Jenoobi
{"title":"Erlotinib.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Al-Kahtani,&nbsp;Fahad I Al-Jenoobi","doi":"10.1016/bs.podrm.2019.10.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.004","url":null,"abstract":"<p><p>Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells. This study presents a comprehensive profile of erlotinib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography, and high-performance liquid chromatography. Pharmacology of erlotinib including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 48 references.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37731932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meloxicam. Meloxicam。
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-12 DOI: 10.1016/bs.podrm.2019.10.006
Nasr Y Khalil, Khalid F Aldosari
{"title":"Meloxicam.","authors":"Nasr Y Khalil,&nbsp;Khalid F Aldosari","doi":"10.1016/bs.podrm.2019.10.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.006","url":null,"abstract":"<p><p>Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Index 指数
Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 DOI: 10.1016/s1871-5125(20)30010-8
{"title":"Index","authors":"","doi":"10.1016/s1871-5125(20)30010-8","DOIUrl":"https://doi.org/10.1016/s1871-5125(20)30010-8","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(20)30010-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56843391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cocrystal Systems of Pharmaceutical Interest: 2012-2014. 医药领域的共晶系统:2012-2014。
Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2018-12-21 DOI: 10.1016/bs.podrm.2018.11.004
Harry G Brittain
{"title":"Cocrystal Systems of Pharmaceutical Interest: 2012-2014.","authors":"Harry G Brittain","doi":"10.1016/bs.podrm.2018.11.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.004","url":null,"abstract":"<p><p>Developments in the field of pharmaceutical cocrystals have been documented in the form of chronological review articles, and the present review encompasses articles published during 2012, 2013, and 2014. Appropriate publications were drawn from the major physical, crystallographic, and pharmaceutical journals, being sorted according to the identity of the drug substance involved. This information is contained in tabular form, where the primary sorting has been by compound name and year of publication. For each entry, the table also contains the bibliographic citation to the paper, a complete list of the authors, and the title of the paper.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Thiouracil: Comprehensive profile. 硫脲嘧啶:综合概况。
Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2019-01-10 DOI: 10.1016/bs.podrm.2018.11.006
Nasr Y Khalil, Haitham K AlRabiah, Mohammed S Almousa, Ahmed Bari, Hamad M Alkahtani
{"title":"Thiouracil: Comprehensive profile.","authors":"Nasr Y Khalil,&nbsp;Haitham K AlRabiah,&nbsp;Mohammed S Almousa,&nbsp;Ahmed Bari,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2018.11.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.006","url":null,"abstract":"<p><p>Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信